PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565662
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565662
Saliva-based Screening Market size was valued at USD 350.90 Million in 2023, expanding at a CAGR of 8.20% from 2024 to 2032.
The Saliva-Based Screening Market focuses on diagnostic tests that use saliva samples for detecting various conditions, offering a non-invasive alternative to traditional methods. The market is expanding due to increasing demand for convenient and accurate diagnostic solutions. For example, during the COVID-19 pandemic, saliva-based tests gained prominence as they provided a less invasive method for large-scale testing, with over 10 million tests conducted globally in 2021. However, the market faces challenges such as variability in saliva sample quality and limited standardization across tests. Opportunities are emerging from advancements in saliva-based genetic testing and the development of new diagnostic assays for chronic diseases and infections. Additionally, the growing trend toward personalized medicine and increased funding for non-invasive diagnostic research are expected to drive further growth in this sector. The rise in preventive healthcare and self-testing also contributes to the expanding adoption of saliva-based screening solutions.
Saliva-based Screening Market- Market Dynamics
Increasing Demand for Convenient and Accurate Diagnostic Solutions Fuels Growth in Saliva-Based Screening Market
The increasing demand for convenient and accurate diagnostic solutions is significantly fueling growth in the Saliva-Based Screening Market. For instance, the U.S. Food and Drug Administration (FDA) approved several saliva-based COVID-19 tests during the pandemic, with over 8 million tests authorized for emergency use by late 2021. The Centers for Disease Control and Prevention (CDC) highlighted the benefits of these tests for their ease of use and reduced discomfort compared to nasal swabs. Furthermore, advancements in genetic testing using saliva, such as those developed by companies like 23andMe, are enhancing diagnostic accuracy and consumer accessibility. The push towards non-invasive, user-friendly testing methods aligns with broader healthcare trends emphasizing patient comfort and ease of use, driving the market's expansion. The integration of saliva-based tests into routine health monitoring and preventive care further supports this growing demand.
Saliva-based Screening Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.20% over the forecast period (2024-2032)
Based on Type segmentation, Polymerase Chain Reaction (PCR) was predicted to show maximum market share in the year 2023
Based on application segmentation, Infectious Disease Detection was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Saliva-based Screening Market is segmented on the basis of Type, Application, End-User, and Region.
The market is divided into four categories based on Type: Enzyme-Linked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), and Biosensors. Polymerase Chain Reaction (PCR) leads the market due to its high sensitivity and accuracy. Enzyme-linked immunosorbent Assay (ELISA) follows, offering reliable detection in various applications. Lateral Flow Assay (LFA) is popular for its simplicity, while biosensors are emerging with innovative capabilities.
The market is divided into four categories based on application: Infectious Disease Detection, Drug and Alcohol Testing, Genetic Testing, and Hormonal Testing. Infectious disease detection is the leading application due to the high demand for non-invasive testing methods. Genetic testing follows, driven by advancements in personalized medicine. Drug and alcohol testing is significant, while hormonal testing, though important, is less prevalent in saliva-based diagnostics.
Saliva-based Screening Market- Geographical Insights
The Saliva-Based Screening Market exhibits notable regional differences, with North America leading due to advanced healthcare infrastructure and high adoption rates. In the U.S., the FDA's authorization of saliva-based COVID-19 tests during the pandemic facilitated widespread use, with over 6 million tests conducted in 2022 alone. Europe follows, with countries like the UK and Germany integrating saliva-based diagnostics into their healthcare systems. For example, the UK's National Health Service (NHS) has incorporated saliva tests for various health conditions, enhancing diagnostic accessibility. The Asia-Pacific region, particularly Japan and South Korea, is experiencing rapid growth due to increased investments in healthcare technology and rising awareness of non-invasive testing methods. In Japan, the Ministry of Health has supported the development and use of saliva-based diagnostics for chronic disease management. Latin America and the Middle East & Africa are emerging markets, driven by expanding healthcare infrastructure and increasing public health initiatives promoting non-invasive diagnostic solutions.
Leading companies like OraSure Technologies have expanded their product offerings through partnerships, such as their collaboration with the Bill & Melinda Gates Foundation to enhance the accessibility of saliva-based HIV testing in low-income countries. PerkinElmer has been at the forefront with innovations in saliva-based diagnostics for COVID-19, acquiring diagnostic company BioLegend to boost its capabilities. Additionally, Spectrum Solutions partnered with the University of Illinois to develop saliva-based testing for COVID-19, resulting in over 1 million tests being processed within months. 23andMe continues to pioneer saliva-based genetic testing, expanding its reach through collaborations with pharmaceutical companies for research purposes. These companies are driving market growth through acquisitions, partnerships, and product innovation, enhancing the accessibility and efficiency of saliva-based diagnostics.
In August 2024, Lord's Mark Microbiotech plans to launch a saliva-based organ age test, assessing the biological age of organs using epigenetics. Priced between Rs 15,000 and 20,000, it aims to provide personalized health insights and promote proactive healthcare interventions.
In July 2021, Bio Farma and Nusantics launched a limited Bio Saliva COVID-19 PCR detection test using a gargle method. This innovative approach aims to simplify testing and increase accessibility, enhancing efforts to manage and control the spread of COVID-19.